Previous systematic reviews have assessed the prevalence and odds ratio (OR) of depression for patients with psoriatic disease. Due to probable bidirectional effects, prevalence and prevalence ORs are difficult to interpret. No prior reviews have quantified the relative risk (RR) of depression following a diagnosis of psoriatic disease.
Objective
To estimate the RR of depression in individuals with psoriasis and in psoriatic arthritis (PsA), clear-to-moderate psoriasis, and moderate-to-severe psoriasis subgroups.
Methods
Observational studies investigating the risk of depression in adults with psoriatic disease were systematically searched for in Medline, EMBASE, PsycINFO, and CINAHL databases; 4989 unique references were screened. Studies that reported measures of incident depression in psoriasis patients were included. Thirty-one studies were included into the systematic review, of which 17 were meta-analyzed. Random effects models were employed to synthesize relevant data. Sources of heterogeneity were explored with subgroup analysis and meta-regression.
Results
Seventeen studies were included in meta-analyses. The pooled RR of depression in psoriasis patients compared to nonpsoriasis controls was 1.48 (95% CI: 1.16-1.89). Heterogeneity was high (I2 = 99.8%). Subgroup analysis and meta-regression did not indicate that PsA status or psoriasis severity (clear-to-mild, moderate-to-severe) were sources of heterogeneity. No evidence of publication bias was found.
Conclusions
This review demonstrates that the risk of depression is greater in patients with psoriasis and PsA. Future research should focus on developing strategies to address the mental health needs of this patient population for depression, including primary prevention, earlier detection, and treatment strategies.
MillerIM.EllervikC.YazdanyarS.JemecGB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014-1024.doi:10.1016/j.jaad.2013.06.053http://www.ncbi.nlm.nih.gov/pubmed/24238156
2.
World Health Organization. Global report on psoriasis. World Health Organization; 2016.
3.
TampaM.SarbuM-I.MitranM-I.MitranC-I.MateiC.GeorgescuS-R. The pathophysiological mechanisms and the quest for biomarkers in psoriasis, a stress-related skin disease. Dis Markers. 2018;2018:1-14.doi:10.1155/2018/5823684http://www.ncbi.nlm.nih.gov/pubmed/29619128
4.
KooJ.MarangellLB.NakamuraMet al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31(12):1999-2009.doi:10.1111/jdv.14460http://www.ncbi.nlm.nih.gov/pubmed/28681405
5.
MolteniS.RealiE. Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis. Psoriasis: Targets and Therapy. 2012;2:55-66.
6.
TohidH.AleemD.JacksonC. Major depression and psoriasis: a psychodermatological phenomenon. Skin Pharmacol Physiol. 2016;29(4):220-230.doi:10.1159/000448122http://www.ncbi.nlm.nih.gov/pubmed/27536769
7.
DowlatshahiEA.WakkeeM.ArendsLR.NijstenT. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542-1551.doi:10.1038/jid.2013.508http://www.ncbi.nlm.nih.gov/pubmed/24284419
8.
EspositoM.SaracenoR.GiuntaA.MaccaroneM.ChimentiS. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123-127.doi:10.1159/000090652http://www.ncbi.nlm.nih.gov/pubmed/16484818
9.
FortuneDG.RichardsHL.CorrinA.TaylorRJ.GriffithsCE.MainCJ. Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. J Behav Med. 2003;26(3):211-224.doi:10.1023/A:1023408503807http://www.ncbi.nlm.nih.gov/pubmed/12845935
10.
RichardsHL.FortuneDG.WeidmannA.SweeneySKT.GriffithsCEM. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol. 2004;151(6):1227-1233.doi:10.1111/j.1365-2133.2004.06221.xhttp://www.ncbi.nlm.nih.gov/pubmed/15606519
11.
AlinaghiF.CalovM.KristensenLEet al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):e19:251-265.doi:10.1016/j.jaad.2018.06.027http://www.ncbi.nlm.nih.gov/pubmed/29928910
12.
MoherD.ShamseerL.ClarkeMet al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1doi:10.1186/2046-4053-4-1http://www.ncbi.nlm.nih.gov/pubmed/25554246
13.
StroupDF.BerlinJA.MortonSCet al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008-2012.
14.
DownsSH.BlackN. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384.doi:10.1136/jech.52.6.377http://www.ncbi.nlm.nih.gov/pubmed/9764259
15.
DerSimonianR.LairdN. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.doi:10.1016/0197-2456(86)90046-2http://www.ncbi.nlm.nih.gov/pubmed/3802833
16.
DaviesHT.CrombieIK.TavakoliM. When can odds ratios mislead?BMJ. 1998;316(7136):989-991.doi:10.1136/bmj.316.7136.989http://www.ncbi.nlm.nih.gov/pubmed/9550961
17.
StataCorp. Stata Statistical Software: Release 16. StataCorp LLC; 2019.
18.
AbuabaraK.LeeH.KimballAB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165(5):1066-1073.doi:10.1111/j.1365-2133.2011.10525.xhttp://www.ncbi.nlm.nih.gov/pubmed/21777216
19.
BangCH.YoonJW.ChunJHet al. Association of psoriasis with mental health disorders in South Korea. JAMA Dermatol. 2019;155(6):747-749.doi:10.1001/jamadermatol.2019.0315http://www.ncbi.nlm.nih.gov/pubmed/31066862
20.
BurnsL.DutzJ.ChoiH. The independent impact of depression on incident myocardial infarction in psoriatic disease: a population-based cohort study.: 1036. Arthritis Rheum. 2013;65
21.
DommaschE.LiT.LiY.QureshiAA. Increased risk of incident depression in psoriasis patients. J Invest Dermatol. 2014;134(Suppl 1):S55
22.
DommaschED.LiT.OkerekeOI.LiY.QureshiAA.ChoE. Risk of depression in women with psoriasis: a cohort study. Br J Dermatol. 2015;173(4):975-980.doi:10.1111/bjd.14032http://www.ncbi.nlm.nih.gov/pubmed/26186277
23.
DreganA.MatchamF.Harber-AschanLet al. Common mental disorders within chronic inflammatory disorders: a primary care database prospective investigation. Ann Rheum Dis. 2019;78(5):688-695.doi:10.1136/annrheumdis-2018-214676http://www.ncbi.nlm.nih.gov/pubmed/30846444
24.
EgebergA.ThyssenJP.WuJJ.SkovL. Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2019;180(1):116-121.doi:10.1111/bjd.17208http://www.ncbi.nlm.nih.gov/pubmed/30229872
25.
FeldmanSR.HurP.ZhaoYet al. Incidence rates of comorbidities among patients with psoriasis in the United States. Dermatol Online J. 2018;24(10):1http://www.ncbi.nlm.nih.gov/pubmed/30677809
26.
FeldmanSR.ZhaoY.ShiL.TranMH.LuJ. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res. 2015;67(5):708-717.doi:10.1002/acr.22492http://www.ncbi.nlm.nih.gov/pubmed/25303478
27.
GealeK.HenrikssonM.JokinenJ.Schmitt-EgenolfM. The Relationship Between Psoriasis, Comorbidities, and Depression Onset: A Nationwide Observational Control Study. Acta Dermato-Venereologica; 2018: Tradgardsgatan 14, Uppsala, SE-753 09, Sweden.
28.
HagbergKW.LiL.PengM.ShahK.ParisM.JickS. Incidence rates of suicidal behaviors and treated depression in patients with and without psoriatic arthritis using the clinical practice research Datalink. Mod Rheumatol. 2016;26(5):774-779.doi:10.3109/14397595.2015.1136726http://www.ncbi.nlm.nih.gov/pubmed/26882216
29.
HuSC-S.YuanS-SF.ChenG-S.TuH-P. Increased incidence of ischaemic heart disease and cerebrovascular disease in psoriasis patients with depression: a nationwide retrospective cohort study. J Eur Acad Dermatol Venereol. 2019;33(8):1547-1554.doi:10.1111/jdv.1561630977931
30.
IghaniA.GeorgakopoulosJR.ZhouLL.WalshS.ShearN.YeungJ. Efficacy and safety of apremilast monotherapy for moderate to severe psoriasis: retrospective study. J Cutan Med Surg. 2018;22(3):290-296.doi:10.1177/1203475418755982http://www.ncbi.nlm.nih.gov/pubmed/29373924
31.
KaineJ.SongX.KimG.HurP.PalmerJB. Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. J Manag Care Spec Pharm. 2019;25(1):122-132.doi:10.18553/jmcp.2018.17421http://www.ncbi.nlm.nih.gov/pubmed/29694270
32.
KaineJ.SongX.LenhartG.PalmerJ. Examining the Impact of Psoriatic Arthritis on Risk of Developing New Comorbidities. Academy of Managed Care Pharmacy Nexus. Journal of Managed Care & Specialty Pharmacy; 2016.
33.
KimT.JeonJ.JungKet al. 100 the risk of psychiatric disorders among patients with psoriasis in Korea: a 12-year nationwide population-based cohort study. J Invest Dermatol. 2019;139(9):S231.doi:10.1016/j.jid.2019.07.104
34.
KurdSK.TroxelAB.Crits-ChristophP.GelfandJM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895.doi:10.1001/archdermatol.2010.186http://www.ncbi.nlm.nih.gov/pubmed/20713823
35.
LeeM-S.LinR-Y. The risk of incident depression and anxiety in patients with psoriasis: a population-based cohort study. J Am Acad Dermatol. 2012;66(4)
36.
LeisnerMZ.RiisJL.SchwartzS.IversenL.ØstergaardSD.OlsenMS. Psoriasis and risk of mental disorders in Denmark. JAMA Dermatol. 2019;155(6):745-747.doi:10.1001/jamadermatol.2019.0039http://www.ncbi.nlm.nih.gov/pubmed/31066861
37.
LewinsonRT.VallerandIA.LowerisonMWet al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J Invest Dermatol. 2017;137(4):828-835.doi:10.1016/j.jid.2016.11.032http://www.ncbi.nlm.nih.gov/pubmed/28237512
38.
MargolisDJ.ShinD.NoeMHet al. Lack of association of biologic therapy for psoriasis with psychiatric illness: an electronic medical records cohort study. J Am Acad Dermatol. 2019;81(3):709-716.doi:10.1016/j.jaad.2019.04.055http://www.ncbi.nlm.nih.gov/pubmed/31054973
39.
MerolaJF.HerreraV.PalmerJB. FRI0580 Comorbidity burden and medication use between psoriatic arthritis patients with moderate-tosevere psoriasis vs. those with minimal skin psoriasis in the US. Ann Rheum Dis. 2016;75(Suppl 2):651-652.doi:10.1136/annrheumdis-2016-eular.3816
40.
PazminoS.StoutenV.VerschuerenPet al. SAT0593 incidence of rheumatoid arthritis, psoriatic arthritis and spondyloarthritis and their associated comorbidities in a Belgian GP registry. BMJ Publishing Group Ltd. 2019
41.
PilonD.TeepleA.ZhdanavaMet al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Managed Care & Spec Pharm. 2018;24(4-A Suppl):S82
42.
ShahK.MellarsL.ChangolkarA.FeldmanSR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287-292.doi:10.1016/j.jaad.2017.03.037http://www.ncbi.nlm.nih.gov/pubmed/28623046
43.
ShahK.ParisM.MellarsL.ChangolkarA.MeasePJ. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open. 2017;3(2):e000588doi:10.1136/rmdopen-2017-000588http://www.ncbi.nlm.nih.gov/pubmed/29435363
44.
SoundararajanV.AliY.JimenezJ.PuarN.WestD.NardoneB. Chronic skin disorders and risk of depression within a large urban midwestern US dermatology patient population: 8262. J Am Acad Dermatol. 2019;81(4)
45.
StroberB.GooderhamM.de JongEet al. Depressive symptoms, depression, and the effect of biologic therapy among patients in psoriasis longitudinal assessment and registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70-80.doi:10.1016/j.jaad.2017.08.051http://www.ncbi.nlm.nih.gov/pubmed/29102053
46.
WuJJ.PenfoldRB.PrimatestaPet al. The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. J Eur Acad Dermatol Venereol. 2017;31(7):1168-1175.doi:10.1111/jdv.14175http://www.ncbi.nlm.nih.gov/pubmed/28214371
47.
KesslerRC.BrometEJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119-138.doi:10.1146/annurev-publhealth-031912-114409http://www.ncbi.nlm.nih.gov/pubmed/23514317
48.
DavamiMH.BaharlouR.VasmehjaniAAet al. Elevated IL-17 and TGF-β serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder. Basic Clin Neurosci. 2016;7(2):137.doi:10.15412/J.BCN.0307020727303608
49.
de OliveiraPSS.CardosoPRG.LimaEVet al. IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients. Mediators Inflamm. 2015;2015:819149-5.doi:10.1155/2015/819149http://www.ncbi.nlm.nih.gov/pubmed/26351408
50.
BlauveltA.ChiricozziA. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-390.doi:10.1007/s12016-018-8702-3http://www.ncbi.nlm.nih.gov/pubmed/30109481
51.
VallerandIA.LewinsonRT.ParsonsLM.LowerisonMW.PattenSB.BarnabeC. Depression as a risk factor for the development of psoriasis: a retrospective cohort study in the UK. Br J Dermatol. 2020;183(4):776-778.doi:10.1111/bjd.19160http://www.ncbi.nlm.nih.gov/pubmed/32352156
52.
AbbottR.WhearR.NikolaouVet al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: a systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res. 2015;79(3):175-184.doi:10.1016/j.jpsychores.2015.04.008http://www.ncbi.nlm.nih.gov/pubmed/25935351
53.
BasavarajKH.NavyaMA.RashmiR. Relevance of psychiatry in dermatology: present concepts. Indian J Psychiatry. 2010;52(3):270-275.doi:10.4103/0019-5545.70992http://www.ncbi.nlm.nih.gov/pubmed/21180416
54.
ConnorCJ. Management of the psychological comorbidities of dermatological conditions: practitioners’ guidelines. Clin Cosmet Investig Dermatol. 2017;10:117-132.doi:10.2147/CCID.S111041http://www.ncbi.nlm.nih.gov/pubmed/28458571
55.
KroenkeK.SpitzerRL.WilliamsJBW. The patient health questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292.doi:10.1097/01.MLR.0000093487.78664.3Chttp://www.ncbi.nlm.nih.gov/pubmed/14583691
56.
SchmiederA.SchaarschmidtM-L.UmarNet al. Comorbidities significantly impact patients’ preferences for psoriasis treatments. J Am Acad Dermatol. 2012;67(3):363-372.doi:10.1016/j.jaad.2011.08.023http://www.ncbi.nlm.nih.gov/pubmed/22015150
57.
VoorheesASV.FriedR. Depression and quality of life in psoriasis. Postgrad Med. 2009;121(4):154-161.doi:10.3810/pgm.2009.07.2040http://www.ncbi.nlm.nih.gov/pubmed/19641281
58.
FiestKM.JetteN.QuanHet al. Systematic review and assessment of validated case definitions for depression in administrative data. BMC Psychiatry. 2014;14(1):289doi:10.1186/s12888-014-0289-5http://www.ncbi.nlm.nih.gov/pubmed/25322690
59.
MinC.KimM.OhDJ.ChoiHG. Bidirectional association between psoriasis and depression: two longitudinal follow-up studies using a national sample cohort. J Affect Disord. 2020;262:126-132.doi:10.1016/j.jad.2019.10.043http://www.ncbi.nlm.nih.gov/pubmed/31733456
60.
TillettW.SkornickiM.PrinceP.SurukiR.LeeE.LouderA. P280 Clinical burden of concomitant joint disease in psoriasis: a US-linked claims and electronic medical records database analysis. Rheumatology. 2020;59(Suppl_2):keaa111:273.doi:10.1093/rheumatology/keaa111.273
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
